Showing 611-620 of 805 results for "".
- LSU Health New Orleans Develops New Human Cell Line to Study Blinding Eye Disordershttps://modernod.com/news/lsu-health-new-orleans-develops-new-human-cell-line-to-study-blinding-eye-disorders/2481175/Under the direction of Boyd Professor Nicolas Bazan, MD, PhD, scientists at LSU Health New Orleans Neuroscience Center of Excellence have developed a new, experimental human cell line from retinal pigment epithelial cells. Called ABC, these cells so closely resemble and retain the properties of n
- Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2022 American Academy of Ophthalmology Annual Meetinghttps://modernod.com/news/glaukos-technologies-featured-in-numerous-scientific-abstracts-at-the-2022-american-academy-of-ophthalmology-annual-meeting/2481136/Glaukos announced that its technologies will be featured in various scientific programming at the American Academy of Ophthalmology (AAO) annual meeting, being held September 30-October 3, 2022 in Chicago. Key Glaucoma Presentations: Bryan CH Ang, MD Novel
- EyeCare Partners Launches New Innovation Centerhttps://modernod.com/news/eyecare-partners-launches-new-innovation-center/2481118/EyeCare Partners (ECP) announced the launch of the EyeCare Partners Innovation Center, which aims to improve the delivery and quality of eye care and advance clinical eye health education. The Innovation Center will be led by ECP’s Chief Clinical Officer, Antonio Capone, Jr., MD.
- Isarna Therapeutics Presents Update From Phase 2 BETTER Study in Wet AMD and DME at the EURETINA Meetinghttps://modernod.com/news/isarna-therapeutics-presents-update-from-phase-2-better-clinical-study-in-wet-amd-and-dme-at-the-euretina-meeting/2481056/Isarna Therapeutics presented an update from its ISTH0036 clinical development program and the ongoing BETTER Study at the EURETINA meeting in Hamburg, Germany on September 1st, 2022. Marion Munk, MD, PhD, FEBO, and the CMO of Isarna Therapeutics provided initial positive safety results and effic
- BVI Installs First Beyeonics One Systemhttps://modernod.com/news/bvi-installs-first-beyeonics-one-system/2481035/BVI announced that the first Beyeonics One System has been installed at Holzman Solomon Vision Partners, in McClean, Virginia. On August 17, Jonathon Solomon, MD, was the first US surgeon to offer ophthalmic surgery with the Beyeonics One platform in private practice. Under th
- First SBL-3 ClearView Multifocal Intraocular Lens Implanted in UShttps://modernod.com/news/first-sbl-3-clearview-multifocal-intraocular-lens-implanted-in-us/2481031/Lenstec announce that the first US commercial implantations of their newly FDA approved SBL-3 ClearView Multifocal IOL (MIOL) were performed by Jeff Whitsett, MD, of Whitsett Vision, Houston, Texas. The SBL-3 Clearview Multifocal is a next-generation presbyopia-
- First Patients Treated with Lensar's ALLY Adaptive Cataract Treatment Systemhttps://modernod.com/news/first-patients-treated-with-lensars-ally-adaptive-cataract-treatment-system/2481029/Lensar announced the first commercial cases performed with the ALLY Adaptive Cataract Treatment System by Robert Weinstock, MD, at The Eye Institute of West Florida. Dr. Weinstock performed 15 laser-assisted cataract surgery cases following the recent installation of his ALLY Syste
- New App Designed to Use Artificial Intelligence to Reduce Digital Eye Strainhttps://modernod.com/news/new-app-designed-to-use-artificial-intelligence-to-reduce-digital-eye-strain/2481004/Robin Kuriakose, MD, a fellow physician in cornea and refractive surgery at the Northwestern Memorial Hospital, has launched SightKick, a new MacOS application designed to reduce digital eye strain: SightKick. Digital eye strain is a gr
- Opus Genetics Expands its Leadership Teamhttps://modernod.com/news/opus-genetics-expands-its-leadership-team/2480981/Opus Genetics, a gene therapy company developing treatments for inherited retinal diseases, announced the appointments of Vikram Arora, PhD, DABT, as Vice President of Non-Clinical Development; Erin O’Neil, MD, as Vice President of Clinical Development; and Sarah Tuller, JD, RAC, as Vice Pr
- Eyenovia Announces Planned Chief Executive Officer Transitionhttps://modernod.com/news/eyenovia-announces-planned-chief-executive-officer-transition/2480898/Eyenovia announced that Sean Ianchulev, MD, co-founder, chief medical officer, and chief executive officer, will step down as chief executive officer and transition to the role of non-executive Chairman of the Board. The definitive timeline for the transition will be determin